Trials / Completed
CompletedNCT03536949
Study of Safety of RVL-1201 in Treatment of Blepharoptosis
A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety of RVL-1201 in the Treatment of Acquired Blepharoptosis (Study RVL-1201-203)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 234 (actual)
- Sponsor
- RVL Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 9 Years
- Healthy volunteers
- Not accepted
Summary
Phase 3 study to evaluate the extended safety of RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RVL-1201 | RVL-1201 ophthalmic solution, 0.1% |
| OTHER | Vehicle ophthalmic solution | Vehicle placebo ophthalmic solution |
Timeline
- Start date
- 2018-06-20
- Primary completion
- 2019-03-14
- Completion
- 2019-03-27
- First posted
- 2018-05-25
- Last updated
- 2020-09-16
- Results posted
- 2020-09-16
Locations
35 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03536949. Inclusion in this directory is not an endorsement.